Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer

Recruiting now · Phase 2

Conditions studied: Breast Cancer - Infiltrating Ductal Carcinoma, HER-2 Positive Breast Cancer

In brief

The usual approach to care for hormone receptor positive, HER2 positive breast cancer is chemotherapy and HER2 targeted therapy followed by endocrine therapy and surgery. The purpose of this Research Study is to see if taking endocrine therapy with the chemotherapy and HER2 directed therapy increases patients response to therapy at the time of surgery

Key facts

Study ID
NCT07506876
Run by
Legacy Health System
People needed
30
Starts
2026-04-27
Expected to finish
2027-12-01
Last updated by the study team
2026-05-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.